CSCI COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. In addition, it focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.…
Industry Peers
BiotechnologyKey Statistics
About COSCIENS Biopharma (TSE: CSCI)
›
COSCIENS Biopharma (TSE: CSCI) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.
The shares were at 8.250 CAD on 19 November 2026, down 71.1% over 52 weeks. Its 52-week range is 7.000 CAD to 39.60 CAD: the price is 79.2% below the high and 17.9% above the low.
Its market capitalisation is 8.23M CAD.
COSCIENS Biopharma reports return on equity of -269.6%, an operating margin of -56.0% and revenue up 69.7% year over year.
Its debt exceeds its cash by 4.88M USD, a debt-to-equity ratio of 0.56. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.